Pancreatic neuroendocrine tumors. Current treatment concepts

被引：0

作者：

Rinke, A. ^{[1
]}

Gress, T. M. ^{[1
]}

机构：

[1] UKGM Univ Klinikum Giessen & Marburg GmbH, Klin Gastroenterol Endokrinol Stoffwechsel & Klin, Standort Marburg, Baldingerstr, D-35043 Marburg, Germany

来源：

INTERNIST | 2019年 / 60卷 / 03期

关键词：

Neuroendocrine carcinoma; Combined modality therapy; Prognosis/neuroendocrine tumors; Receptors; somatostatin; Positron emission tomography computed tomography; RADIOLABELED SOMATOSTATIN ANALOG; TOXICITY; EFFICACY;

D O I：

10.1007/s00108-018-0545-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The number of cases diagnosed as pancreatic neuroendocrine neoplasia (pNEN) is steadily increasing. The 2017 World Health Organization classification defines anew subgroup of morphologically well differentiated tumors with an elevated proliferation rate (Ki-67 over 20%) as neuroendocrine tumor (NET) G3. Due to the heterogeneity of pNEN regarding etiology (sporadic versus hereditary), symptoms (hormone syndrome versus non-functional tumor), and prognosis (ranging from benign behavior to highly malignant), multidisciplinary management by experienced physicians is required. This is especially true as the number of therapeutic options has increased, while we still lack comparative trials. This overview aims to summarize the multidisciplinary therapeutic options, their selection criteria and the recommendations of the new German S2k guideline.

引用

页码：247 / 256

页数：10

共 19 条

[1]

[Anonymous], 2017, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, V4th

[2] Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity [J].

Antonodimitrakis, Pantelis Clewemar ;

Sundin, Anders ;

Wassberg, Cecilia ;

Granberg, Dan ;

Skogseid, Britt ;

Eriksson, Barbro .

NEUROENDOCRINOLOGY, 2016, 103 (3-4) :345-353

[3] Chemotherapy [J].

Arnold, R ;

Rinke, A ;

Schmidt, C .

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2005, 19 (04) :649-656

[4] Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors [J].

Cives, M. ;

Ghayouri, M. ;

Morse, B. ;

Brelsford, M. ;

Black, M. ;

Rizzo, A. ;

Meeker, A. ;

Strosberg, J. .

[5] Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours [J].

Dilz, Lisa-Marie ;

Denecke, Timm ;

Steffen, Ingo G. ;

Prasad, Vikas ;

von Weikersthal, Ludwig Fischer ;

Pape, Ulrich-Frank ;

Wiedenmann, Bertram ;

Pavel, Marianne .

EUROPEAN JOURNAL OF CANCER, 2015, 51 (10) :1253-1262

[6] ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas [J].

Garcia-Carbonero, R. ;

Sorbye, H. ;

Baudin, E. ;

Raymond, E. ;

Wiedenmann, B. ;

Niederle, B. ;

Sedlackova, E. ;

Toumpanakis, C. ;

Anlauf, M. ;

Cwikla, J. B. ;

Caplin, M. ;

O'Toole, D. ;

Perren, A. .

NEUROENDOCRINOLOGY, 2016, 103 (02) :186-194

[7] Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers [J].

Imhof, Anna ;

Brunner, Philippe ;

Marincek, Nicolas ;

Briel, Matthias ;

Schindler, Christian ;

Rasch, Helmut ;

Maecke, Helmut R. ;

Rochlitz, Christoph ;

Mueller-Brand, Jan ;

Walter, Martin A. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) :2416-2423

[8] Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms - Predictive and Prognostic Markers for Treatment Stratification [J].

Krug, Sebastian ;

Boch, Michael ;

Daniel, Hanna ;

Nimphius, Wilhelm ;

Mueller, Daniela ;

Michl, Patrick ;

Rinke, Anja ;

Gress, Thomas Matthias .

PLOS ONE, 2015, 10 (12)

[9] Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate:: Toxicity, efficacy, and survival [J].

Kwekkeboom, Dik J. ;

de Herder, Wouter W. ;

Kam, Boen L. ;

van Eijck, Casper H. ;

van Essen, Martijn ;

Kooij, Peter P. ;

Feelders, Richard A. ;

van Aken, Maarten O. ;

Krenning, Eric P. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2124-2130

[10] Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors [J].

Mueller, Daniela ;

Krug, Sebastian ;

Majumder, Moushumee ;

Rinke, Anja ;

Gress, Thomas Matthias .

BMC CANCER, 2016, 16

← 1 2 →